Transforming Healthcare Ecosystems with Artificial Intelligence

by GeneOnline
Share To

Two sessions over two days devoted entirely to AI

Artificial Intelligence (AI) is the new buzzword in biomedicine, and for good reason. With the potential to drastically reduce the time and cost burdens of drug development, the biggest names in Big Pharma are already utilizing this powerful tool. AI is increasingly important in today’s ‘smart’ healthcare settings; assisting in hospital admission triage and patient management, ‘viewing’ and analyze medial images to detect breast and other cancers, and identifying disease biomarkers for conditions such as Alzheimer’s. A vital tool in the pandemic era, AI has proven its worth in time-critical case tracking assignments and other epidemiological tasks.

A reflection of its importance, BIO Asia–Taiwan 2020 has dedicated two sessions over two days entirely to AI, with a twelve international speakers presenting the latest advances, case studies and future application scenarios for this exciting new technology.

Don’t miss Leo Anthony Celi, Principal Research Scientist, Massachusetts Institute of Technology, with his presentation ‘Battling the Pandemic with Open Science and Cross-Disciplinary Collaboration’; Faisal Khan of AstraZeneca with his talk ‘How to Apply AI to Different Stages of Drug Development’; and Joris Van Dam and Stephane Wolf of Novartis with his presentation ‘Why and How Pharma Use AI in Digital Therapeutics Platform’. Catch these and more AI-focused presentations and panel discussions at Sessions 7 and 14, BIO Asia–Taiwan 2020.


© All rights reserved. Collaborate with us:
Related Post
CVS Adds Oak Street Health In $10.6 Billion Buy To Boost Primary Care Offerings
Insilico Makes its Biggest AI Deal Ever with Sanofi for Potential $1.2 Billion
35% of Americans May Avoid Seeking Care Due to Concerns Over Healthcare Prices
AbbVie Unveils Latest Data For Skyrizi In Difficult-To-Treat Psoriasis
Sanofi Slashes Insulin Prices by Up to 78% Following Hot On the Heels of Major Competitors
Novartis Snags Pediatric Brain Cancer Indication for Oncology Combination Therapy
Pfizer, Astellas’ Prostate Cancer Drug Xtandi Achieves Goals In Phase 3
Amgen Faces Class Action Lawsuit for Concealing $10.7 Billion Tax Bill to Manipulate Stock Price
ImmunoPrecise Antibodies, Libera Bio Ink $155 Million Pact To Deliver Antibodies With Nanotechnology
Dermavant Eyes Second Vtama Indication with Topline Atopic Dermatitis Results
Scroll to Top